MedTrace Logo

Nelfinavir Mesylate and Bortezomib in Treating Patients With Relapsed or Progressive Advanced Hematologic Cancer

NCT01164709 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 18

Last updated 2019-05-15

No results posted yet for this study

Summary

RATIONALE: Nelfinavir mesylate and bortezomib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Bortezomib may also stop the growth of hematologic cancer by blocking blood flow to the cancer. Giving nelfinavir mesylate together with bortezomib may kill more cancer cells.

PURPOSE: This phase I trial is studying the side effects and best dose of nelfinavir mesylate when given together with bortezomib in treating patients with relapsed or progressive advanced hematologic cancer.

Conditions

  • Leukemia
  • Lymphoma
  • Mature T-cell and Nk-cell Neoplasms
  • Multiple Myeloma and Plasma Cell Neoplasm

Interventions

DRUG

bortezomib

Bortezomib i.v., day 8, 11, 15, 18; 1.3 mg/m2

DRUG

nelfinavir mesylate

p.o., days 1 to 21; dose level: (625), 1250, 1875, or 2500 mg, 2x/d

Sponsors & Collaborators

  • Swiss Cancer Institute

    lead OTHER

Principal Investigators

  • Christoph Driessen, MD · Cantonal Hospital of St. Gallen

  • Dagmar Hess, MD · Cantonal Hospital of St. Gallen

  • Roger von Moos, MD · Kantonsspital Graubuenden

  • Thomas Pabst, MD · Insel Gruppe AG, University Hospital Bern

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-07-31
Primary Completion
2012-07-31
Completion
2013-11-30

Countries

  • Switzerland

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01164709 on ClinicalTrials.gov